Skip to main content
Civic Center, Bahria Town, Islamabad

Kadcyla® 100mg Injection (Trastuzumab Emtansine) – Targeted Therapy (Rx)

₨103,800.00

Important: MedHub does not provide medical advice, diagnosis, treatment recommendations, or dosage guidance. Always consult a qualified doctor or pharmacist before starting, stopping, or changing any medicine. Prescription medicines are supplied only after applicable prescription verification and subject to availability.

Additional information

Generic Name

Trastuzumab Emtansine

Strength

100mg

Dosage Form

Powder for concentrate for solution for infusion

Manufacturer

F. Hoffmann-La Roche Ltd

Storage

2–8°C, do not freeze

Prescription

Prescription only (Rx)

Quick answer: Kadcyla 100mg (trastuzumab emtansine) is an antibody-drug conjugate for HER2-positive breast cancer, used after surgery when some cancer remains and for breast cancer that has spread. A nurse gives it as a drip into a vein every three weeks. MedHub supplies it on prescription with cold-chain delivery across Pakistan.

Patient and caregiver information

What is Kadcyla 100mg?

Kadcyla 100mg is Roche’s brand of trastuzumab emtansine, also called T-DM1. It joins two medicines into one molecule: trastuzumab, an antibody that finds the HER2 protein on breast cancer cells, and DM1, a strong chemotherapy that stops cells dividing. The antibody acts like a delivery van, carrying the chemotherapy straight into HER2-positive cancer cells while sparing much of the healthy tissue. It is not the same as plain trastuzumab and the two must never be swapped.

What is it used for?

Oncologists prescribe it only for HER2-positive breast cancer:

  • Early breast cancer: after surgery, when cancer is still found in the breast or lymph nodes despite earlier treatment with a taxane and trastuzumab.
  • Metastatic or inoperable breast cancer: in patients who have already received trastuzumab and a taxane.

Your doctor confirms HER2 status on a tissue test before starting treatment.

How is it given?

Kadcyla 100mg is given by trained healthcare staff in a hospital or clinic, as an injection or infusion. Your doctor decides the dose and the treatment schedule.

Common side effects

  • Tiredness, headache and muscle or joint aches
  • Nausea and constipation
  • Low platelet count, causing nosebleeds or easy bruising
  • Raised liver enzymes on blood tests
  • Tingling or numbness in the hands and feet

Contact your care team straight away if you notice yellow skin or eyes, dark urine, bleeding that is hard to stop, new breathlessness or a dry cough, or swollen ankles.

Storage and transportation

Transportation of cold-chain products must go through the dispensing pharmacy and follow the manufacturer’s instructions. Ask your dispensing pharmacist if you have any questions about handling.

How to order from MedHub

  1. Send a photo of your prescription on WhatsApp.
  2. Our pharmacist confirms the price and stock with you.
  3. We pack the vial in a cold-chain box and deliver it to your city or hospital.

Families in the UAE, UK and Saudi Arabia often arrange Kadcyla 100mg for mothers and sisters in Pakistan through us. Larger doses usually combine this vial with Kadcyla 160mg. Patients earlier in treatment may receive Herceptin 440mg (trastuzumab). See all our oncology medicines.

For healthcare professionals

  • Composition: trastuzumab emtansine 100 mg per single-dose vial, powder for concentrate for solution for infusion (20 mg/ml after reconstitution with 5 ml water for injection)
  • Drug class: HER2-directed antibody-drug conjugate
  • Indications: adjuvant treatment of HER2-positive early breast cancer with residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane and HER2-targeted therapy; HER2-positive unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane, separately or in combination
  • Mechanism: trastuzumab binds HER2 subdomain IV; after internalization and lysosomal degradation, DM1 (a maytansine derivative linked by a stable thioether linker) is released and inhibits microtubule assembly, causing cell cycle arrest and apoptosis; retains trastuzumab-mediated ADCC and HER2 signalling inhibition
  • Label dose: 3.6 mg/kg IV every 3 weeks; first infusion over 90 minutes, later infusions over 30 minutes if tolerated; early breast cancer for 14 cycles unless recurrence or unacceptable toxicity; metastatic disease until progression; do not exceed 3.6 mg/kg and do not substitute with trastuzumab
  • Monitoring / key precautions: LVEF before and regularly during treatment; serum transaminases and bilirubin before each dose (hepatotoxicity, nodular regenerative hyperplasia); platelet count before each dose; watch for interstitial lung disease, infusion reactions, haemorrhage and peripheral neuropathy; embryo-fetal toxicity, effective contraception required
  • Storage: 2–8°C, do not freeze
  • Manufacturer: F. Hoffmann-La Roche Ltd, Switzerland
  • Marketed in Pakistan by: Roche Pakistan Ltd
  • Pack: 1 vial

Frequently asked questions

What is Kadcyla 100mg?

Kadcyla 100mg is Roche's brand of trastuzumab emtansine, also called T-DM1.

What is Kadcyla 100mg used for?

Kadcyla 100mg treats HER2-positive breast cancer, both early cancer that remains after pre-surgery treatment and breast cancer that has spread after trastuzumab and a taxane.

How is Kadcyla 100mg given?

Kadcyla 100mg is given by trained healthcare staff in a hospital or clinic, as an injection or infusion. Your doctor decides the dose and the treatment schedule.

How does Kadcyla 100mg work?

Kadcyla 100mg combines the antibody trastuzumab with a chemotherapy medicine called DM1. The antibody part travels through the bloodstream and attaches to HER2 receptors on breast cancer cells. The cell then pulls the medicine inside, where DM1 is released. DM1 disrupts the tiny tubes that cells need to divide, so the cancer cell dies. The antibody part also blocks HER2 growth signals.

What precautions should I know before using Kadcyla 100mg?

Before treatment, tell your doctor about any heart disease, liver problems, lung disease, low platelets, bleeding problems or use of blood thinners. It is a different medicine from plain trastuzumab, and the two cannot be swapped. Use effective contraception during treatment and for seven months afterwards, and do not breastfeed. Report straight away yellow skin, dark urine, breathlessness, a cough, swollen ankles, nosebleeds or other unusual bleeding, or numbness in the hands or feet.

What is the Kadcyla 100mg price in Pakistan?

Kadcyla 100mg costs Rs 103,800 per vial. Contact MedHub to confirm current price, availability and delivery options.

Can I get Kadcyla 100mg in Lahore, Karachi or Peshawar?

Yes. MedHub serves patients across Pakistan, including Islamabad, Rawalpindi, Lahore, Karachi, Peshawar, Multan and Faisalabad. Contact MedHub to confirm current price, availability and delivery options.

Do I need a prescription to buy Kadcyla 100mg?

Yes. Kadcyla 100mg is a prescription-only medicine. Send a clear photo of your doctor's prescription on WhatsApp, and our pharmacist checks it before confirming your order.

Can I order Kadcyla 100mg for my family in Pakistan from abroad?

Yes. People in the UAE, UK and Saudi Arabia order Kadcyla 100mg through MedHub for their family in Pakistan. Share the prescription on WhatsApp, and our team guides you through payment and delivery to their home or hospital.

Sources: FDA prescribing information for healthcare professionals. MedHub writes its own plain-language summaries. Always read the leaflet supplied with your medicine.

Questions about your treatment or outcome? Consult your doctor.

Questions about this medicine, availability or price? Consult our pharmacist on WhatsApp or call 0333 4575527.

This information is for general awareness only and is not medical advice. Always consult your doctor before starting, stopping or changing any medicine.

Reviews

There are no reviews yet.

Be the first to review “Kadcyla® 100mg Injection (Trastuzumab Emtansine) – Targeted Therapy (Rx)”

Your email address will not be published. Required fields are marked *

Contact Us